Table Randomized Controlled Trials of Cholesterol Reduction Reported After Publication of 2004 Clinical Trial Regulations

ACCELERATE = Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes; ACS = acute coronary syndrome; AIM-HIGH = Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; ASCVD = atherosclerotic cardiovascular disease; ASPEN = Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus; AURORA = A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis—An Assessment of Survival and Cardiovascular Events; CCS = coronary calcium score; CHD = coronary heart disease; CI = confidence interval; CKD = chronic kidney disease; CORONA = Controlled Rosuvastatin in Multinational Trial in Heart Failure; CV = cardiovascular; CVD = cardiovascular disease; EMPATHY = Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy; ER = extended release; FIELD = Fenofibrate Intervention and Event Lowering in Diabetes; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; GISSI-HF = Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca Heart Failure; HBP = high blood pressure; HDL = high-density lipoprotein; HF = heart failure; HIJ-PROPER = Heart Institute of Japan–Proper Level of Lipid Lowering with Pitavastatin and Ezetimibe in Acute Coronary Syndrome; HOPE-3 = Heart Outcomes Prevention Evaluation–3; HR = hazard ratio; HPS2-THRIVE = Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events; hsCRP = highly sensitive C-reactive protein; IDEAL = Incremental Decrease in End Points Through Aggressive Lipid Lowering; ILLUMINATE = Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events; IMPROVE-IT = Improved Reduction in Outcomes: Vytorin Efficacy International Trial; JUPITER = Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LDL = low-density lipoprotein cholesterol; MCE = Minnesota Coronary Experiment; MEGA = Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; MI = myocardial infarction; NR = not reported; ODYSSEY = Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy; PUFA = polyunsaturated fatty acid; REVEAL = Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification; RinR = reduction in risk; RtR = rate ratio; RR = risk ratio; SDHS = Sydney Diet Heart Study; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; SEAS = Simvastatin and Ezetimibe in Aortic Stenosis; SFA = saturated fatty acid; SHARP = Study of Heart and Renal Protection; SPARCL = Stroke Prevention by Aggressive Reduction in Cholesterol Levels; TC = total cholesterol; TNT = Treating to New Targets; T2DM = type 2 diabetes mellitus; WHI = Women's Health Initiative; 4D = Die Deutsche Diabetes Studie.